First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation. Xiong Y, Wang L, Zhang W, Meng Y, et al. BMC Cancer 2024;24:1326.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xiong Y, Wang L, Zhang W, Meng Y, et al. First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation. BMC Cancer 2024;24:1326.
PMID: 39472861